# US 2008/0075774 A1 · Bupropion hydrobromide and therapeutic applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075774 A1
- Document ID: US20080075774A1
- Status: Published application
- Kind: A1
- Application number: 11/834,848
- Filed: 2007-08-07
- Published: 2008-03-27
- Earliest claimed: 2005-06-27
- Assignees: Bioavail Laboratories International S.R.L.
- Inventors: Robert WILLIAMS; Peter SILVERSTONE
- Web page: https://patentgrep.com/patent/US20080075774A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/24: Antidepressants
- A61P 25/34: Tobacco-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

## Claims

### Claim 1

A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
wherein administration of an amount of a bupropion hydrobromide to a first rat results in less incidences of and/or less severe bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.

### Claim 2 (depends on 1)

The composition of claim 1, which is in tablet form.

### Claim 3 (depends on 1)

The composition of claim 1, which is a modified release formulation.

### Claim 4 (depends on 1)

The composition of claim 1, which is in tablet form and wherein the bupropion hydrobromide is contained within a core of the tablet further comprising a coating over the core.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the coating is a controlled release coating.

### Claim 6

A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
wherein administration of about 100 mg/kg of a bupropion hydrobromide to a first rat results in less incidences of and/or severity of bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.

### Claim 7

A method of treating a subject at risk of bupropion-induced seizures in need of bupropion treatment, the method comprising:
administering a composition comprising bupropion hydrobromide to said subject in an amount sufficient to treat said subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition comprises an amount of bupropion hydrobromide chosen from 174 mg, 348 mg and 522 mg.

### Claim 9 (depends on 7)

The method of claim 7, wherein the composition is in tablet form and the administering comprises oral administration.

### Claim 10 (depends on 7)

The method of claim 7, wherein the composition is a modified release formulation.

### Claim 11 (depends on 7)

The method of claim 7, wherein the composition is in tablet form and wherein the bupropion hydrobromide is contained within a core of the tablet further comprising a coating over the core.

### Claim 12 (depends on 7)

The method of claim 7, wherein the coating is a controlled release coating.

### Claim 13

A method of reducing incidences of bupropion-induced seizures comprising:
administering a pharmaceutically effective amount of bupropion hydrobromide to a subject in need of bupropion administration;
wherein incidences of bupropion-induced seizures resulting from the administration of bupropion hydrobromide is less than incidences of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride.

### Claim 14 (depends on 13)

The method of claim 13 wherein bupropion-induced seizures resulting from the administration of bupropion hydrobromide is less severe than bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride.

### Claim 15

A method of reducing incidences of bupropion-induced seizures comprising:
administering a pharmaceutically effective amount of bupropion hydrobromide to a subject in need of bupropion administration;
wherein administration of about 100 mg/kg of the bupropion hydrobromide to a first rat results in less incidences of bupropion-induced seizures when compared to incidences of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of bupropion-induced seizures in the first and second rats are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.

### Claim 16

A method of reducing the incidences of bupropion induced seizures comprising coadministration of a bromide salt with a bupropion salt, wherein the bromide salt is administered in an amount of less than about 3.5 mg/kg.

### Claim 17 (depends on 16)

The method of claim 16 wherein the bromide salt is sodium bromide.

### Claim 18 (depends on 16)

The method of claim 16 wherein the bupropion salt is bupropion hydrochloride.

### Claim 19

A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
wherein administration of about 100 mg/kg of a bupropion hydrobromide used to manufacture the composition to a first rat results in less incidences of and/or severity of bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
